Navigation Links
Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
Date:7/1/2008

n (FDA) for the same indication.

Final Phase 2 Study Results

The Phase 2 talactoferrin monotherapy trial was an open label, 44-patient, single arm trial conducted at six leading U.S. sites. To be eligible, patients with histologically confirmed metastatic or unresectable RCC had to have disease progression after being treated with at least one prior regimen of systemic therapy. Computed tomography (CT) scan documentation of disease progression following the most recent therapy was required. Talactoferrin was administered at a dose of 1.5 grams twice a day in 14-week cycles (12 weeks on, two weeks off) for up to four cycles or until disease progression. The study's co-primary endpoints were to detect an increase in the 14-week progression-free survival (PFS) rate from 20% to 40% or a 12.5% response rate, either of which were considered to be clinically significant. In a Phase 2 trial of Avastin in second line RCC patients, the placebo arm had a 4-month PFS rate of 20%, and was chosen as the historical reference.

All 44 patients were included in the intent-to-treat (ITT) population. The study met the pre-defined target with a 14-week PFS rate of 59% (p<0.0001 for comparison to 20%). The response rate was 4.5%, with 70.5% of patients demonstrating stable disease for at least 8 weeks. The disease control (complete or partial response + stable disease) rate was 75%. The median PFS was 6.4 months. The median overall survival (OS) was 21.1 months, and the 1 year survival rate was 77%. Talactoferrin was well tolerated with no significant hematological, renal or hepatic toxicities reported. In addition, there were no drug related serious adverse events.

About EMEA Orphan Medicinal Product Designation

The Regulation on Orphan Medicinal Products in the European Union (EU) provides incentives for companies developing and marketing therapies for rare diseases, defined as those affecting fewer than five in 10,000 people in the EU. The Regulation
'/>"/>

SOURCE Agennix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
4. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
5. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
6. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
7. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
8. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
9. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
10. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
11. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among ... consolidation of localization purchasing in 2015, says Moravia ... to a recent study by market research firm Common ... single-source solution for their translation and localization needs. "From ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical ... 2019" report to their offering. ... techniques for the detection of infectious diseases. The ...
(Date:1/22/2015)... Md. , Jan. 22, 2015 The Parenteral Drug ... Science Program SM : Enabling Pharmaceutical Manufacturing,s Future. ... fulfill the following goals: , Highlight the ongoing ... Strengthen and build practical solutions by filling known gaps in ...
Breaking Medicine Technology:Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3PDA Launches Manufacturing Science Program(SM) 2PDA Launches Manufacturing Science Program(SM) 3
... , , CARROLLTON, Ga., Dec. 16 ... single-database electronic health record (EHR), practice management and interoperability solution, ... in the annual 2009 Top 20 Best in KLAS ... practices having between six and 25 physicians, Prime Suite ...
... AMSTERDAM, December 16 Today, Avantium ... of its pharmaceutical,business. Gunnar Staaf previously worked at Serentis ... a range of commercial and executive,positions. The appointment is ... business. The company intends to create a,stand-alone pharmaceutical company ...
Cached Medicine Technology:Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Avantium Appoints Gunnar Staaf as CEO Pharma 2
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... be a clue leading researchers at Washington University School ... treatment approach for Niemann-Pick disease, a rare, deadly neurodegenerative ... Niemann-Pick disease, the researchers suggest that chemical compounds could ... control machinery. And they believe the approach also could ...
... manufacturer replaces spreadsheet-based process with ... Xactly Incent on-demand ... Corporation, the leader,in on-demand sales performance management, today announced ... of products designed to,enhance the diagnosis and treatment of ...
... 5 Ingenious Med, leaders in software and,services ... record sales, product deployments, partnerships, and client,expansions in ... increased by,81% over 2006. This increase in sales ... in IM,s overall profitability., In the past ...
... worries hit home, even among the most prosperous, ... by Consumer Reports reveals a significant disconnect: Americans,overwhelmingly support ... access to quality, affordable health care, and a large,majority ... comes to how,those changes should be adopted, there is ...
... best friends tend to become less negative as we age, ... demanding. , That,s according to a University of ... more than 800 adults ages 20 and older. , ... other close relationships enhance well-being," said Kira Birditt, a research ...
... (NYSE: WST ) today announced that Donald E. ... Federici, Chief,Financial Officer, will be presenting at the 2008 ... 11, 2008 in New York City., A copy ... the,investor link of the Company,s website at http://www.westpharma.com ...
Cached Medicine News:Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 2Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 3Health News:Ingenious Med Reports Record Sales and Client Expansions in 2007 2Health News:Consumer Reports Poll: Americans Demand Health Reform But Are Unsure About How to Achieve it 2Health News:Consumer Reports Poll: Americans Demand Health Reform But Are Unsure About How to Achieve it 3Health News:Consumer Reports Poll: Americans Demand Health Reform But Are Unsure About How to Achieve it 4Health News:Seeing our spouses more negatively might be a positive 2Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2
Sealing tape featuring 3M adhesive technology. Compatible with DMSO. Good optical quality. Minimal autofluorescence....
Acetate Plate Sealers 100/Box...
OptiTape - Optically Clear sealing tape for OmniUltra PCR plates. 250 sheet roll....
For use with 96-well plates, catalog # 410150...
Medicine Products: